Drug news
Neupro (UCB) FDA approved for advanced Parkinsons and RLS
advanced Parkinsons and RLS Neupro(rotigotine transdermal system) from UCB/Schwarz is FDA approved as a therapy to treat the signs and symptoms of advanced stage idiopathic Parkinson's Disease and as a treatment for moderate-to-severe primary Restless Legs Syndrome. Neupro was previously approved in the USA as a therapy to treat the signs and symptoms of early stage idiopathic Parkinson's disease.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins